

Ref.-AL/CS/STX/2018/03

February 14, 2018

The Manager (Department of Corporate Services)
Bombay Stock Exchange Limited (BSE)
P.J. Towers, 25th Floor, Dalal Street, Fort
Mumbai- 400001

Scrip Code: <u>526707</u>

The Manager (Listing Department)
National Stock Exchange of India Limited (NSE)
Exchange Plaza, Bandra Kurla Complex
Bandra (East), Mumbai- 400051

Scrip Code: ALCHEM

Sub: Outcome of Board Meeting

Dear Sir/Madam,

We wish to inform you that the Board of Directors in its meeting held on Wednesday 14th February, 2018, has considered and approved the following:

- 1. Unaudited Financial Results (Provisional) of the Company for the quarter / nine months ended on 31st December, 2017. A copy of the results is attached as **Annexure -I**.
- 2. Limited review Report on the Unaudited Financial Results for the quarter / nine months ended on 31st December, 2017 obtained from Statutory Auditors has also been taken on record and a copy of the same is attached as **Annexure-II**.
- 3. Any other matter with permission of the Chair.

An extracts of the aforementioned financial results would be published in the newspaper in accordance with the Listing Regulations.

You are requested to take the above information on your record & acknowledge the same.

Thanking you

Yours Sincerely

For ALCHEMIST LIMITED

For ALCHEMIST LIMITED

Company Secretary

(Company Secretary)

New Delhi

ALCHEMIST LTD.

CIN: L72200DL1988PLC192643

ALCHEMIST LIMITED
REGD.OFFICE: 23 NEHRU PLACE, NEW DELHI-110 019
CIN NO.:L72200DL1988PLC192643. Tel No.: (91-11) 40600800, Fax: (91-11) 40600888. E-mail: info@alchemist.co.in. Website: www.alchemist.co.in

	PART I: STATEMENT OF UNAUDITED STANDALONE FINANCIAL	RESULTS	FOR THE QUART	QUARTER ENDED 31, 12	2017	
			u ≩ ji	₹ in Lacs except EPS	data)	
Z Z	Architect		Quarter Ended		Nine Month Ended	th Ended
3		31.12.2017	30,09,2017	31,12,2016	31.12.17	31.12.16
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
V-4	Net Sales (Net of Excise Duty) / Incomes from Operations	728.58	670.78	613.76	1994.72	1972.90
7	Other Income	50	54.15	45.16	85.08	251.01
ю	Total Revenue (1+2)	730.09	724,94	658.92	2079.80	2223.91
4	Expenditure					
3	a) Consumption of Raw Material & Others	162.71	91.73	91.52	338,11	273.23
	b) Purchase of stock in trade	360.30	344.67	331.00	662.90	980,10
	c) (Increase)/decrease in stack in trade, finished goods and work in progress	147	102,25	4,73	424.87	38,55
	d) Employees benefit expenses	251.65	212.19	432.82	759.65	1161.02
	e) Firstice costs	35.85	45.92	50.25	131.84	167.61
1	f) Depreciation	196.77	198,01	170.071	591,24	603,49
	s) Other Expenditure	may considerable to the second				
	(i) Foreign Exchange (Gain)/Loss	748.55	(323.61)	(632.91)	477.73	(850.19)
	(ii) Other Expenditure other than (i) above	171.79	128.91			757.68
-	Total Expenses	1929.09	80.08	632.63		3131.49
ιC	Profit before Exceptional & Extraordinary Items (3-4)	(1198.99)	(75.14)	26.29	(1805.59)	(907.58)
· C	Exceptional Items	00.0	00.00	000		6871.83
0	Profit Before Tax (7-8)	(1198.99)	(75.14)	26.29	(1805.59)	(7779.41)
10	Tax Expenses	ALCOHOL VICTORIAN CONTRACTOR CONT				
	a) Current Tax	and the second of the second o	1			
!	b) Deferred Tax	82,79	(78.12)			
F	Profit(+)/ Loss(-) for the period (9-10)	(1281.79)	2.98	26.29	(1810.26)	(///9.41)
12	Other Comprehensive Income				MARK SITTLE STATE OF THE STATE	12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	I tems that will not be reclassified to profit or loss	And of the case of the desired states and the case of				000
	Re-measurement of the net defined benefit plans	66.31				800
	Тах оп въоче	(18.59)	e construire de la cons			0.00
	Total Other comprehensive Income, net of fax	47.73	(23.43)	***************************************		3
13	Total comprehensive Income, for the period	(1234.06)	(20.46)			(77/9,41)
5	Paid up equity stare capital	1355.98	1355.98	1355.98	1355.98	1355.98
	(Face Value of ₹ 10/- each per share)					
ស្ដ	Basic and diluted Earning Per Share (EPS) (not annualised)	11. (3	ç	01.0	(13.35)	
	2)SDG~	(04.0)		0,0		(57.37)
	-Dilluted	(27.7)		11.7		

5.No. 1 Segment Revenue (Net) a) Pharma, Chemical b) Agri Business Sub-Total Less Inter Segme Net Sales/In 2 Segment Results Profit/(Loss) before tax a) Pharma, Chemical b) Agri Business Total Less: Exceptional Item & Total Profit before Tax Add: Other Incomes & Of Less: Exceptional Item & Total Profit after Tax 3 Segment Assets a) Pharma, Chemical b) Agri Business Total Assets a) Pharma, Chemical b) Agri Business Total Assets Total Liabilities a) Pharma, Chemical b) Agri Business Total Liabilities						(3 in Lacs)
The state of the s					***************************************	1
the state of the s	5 (4) (4) (5) (4) (4) (4) (4) (4) (4) (4) (4) (4) (4		Quarter Ended		Nine Month	h Ended
	rarranars	31.12.2017	30.09.2017	31.12.2016	31.12.17	31.12.16
	mue (Net)					
	a) Pharma, Chenical & Minerals	488.78	543.41	463.19	1502.30	1567,40
	#Siness	239,80	127.37	150.57	492.42	405.50
		728.58	670.78	613.76	1994,72	1972.90
	Less Inter Segment Revenue	E	generation and the second seco			
	Net Sales/Incomes	728.58	670.78	613.76	1994,72	1972.90
	Profit/(Loss) before tax and interest from segments)					
	a) Pharma, Chemical & Minerals	(1141.67)	(320,15)	(489.75)	(1568.60)	(1570,90)
	SSOURCE	(23.00)	(86.82)	(111.78)	(190.23)	(270.28)
	WANNEY OF THE ART THE STORY OF THE PRINTING OF THE STORY	(1164.66)	(406.97)	(601.54)	(1758.82)	(1841.17)
	Charges	35.85	45.93	50,25	131.84	167.61
	Add: Other Incomes & Other Operative Income		377.76	678.07	85.08	1101.21
Tott Prov Tott Capi	Less: Exceptional Item & unallocated expenses	00.0	00'0	00'0	00.0	6871.83
Prop Total Sega Total	efore Tax	(1198.99)	(75.14)	26.29	(1805.59)	(7779.41)
Seg Seg Tott	axation	82.79	(78.12)		4.67	
Sega Sega Tott	fter Tax	(1281.79)	2.98	26.29	(1810.26)	(7779.41)
Segi Tott	its					
Segi Tott	a) Pharma, Chemical & Minerals	2241.27	2352.32	80,66699	2241.27	80.66699
Segi Tort	nsiness	954.08	859.37	19801.82	954,08	19801.82
Segi Totk		3195.35	3211.69	86800.89	3195.35	86800.89
Cap)	Hites					2000 table to the total table table to the total table t
Capi	a) Pharma, Chemical & Minerals	1434.09	1514.18	30540.52	1434.09	30540.52
- Cap	usiness	141.68	57.46	6627.66	141.68	6627.66
Gg .	53	1575.77	1571.64	37168.18	1575.77	37168.18
(Segment a	pa/				The second state of the se	
a) Pharma	(Segment assets-Segment Liabilities)	The state of the s				
And the second s	a) Pharma, Chemical & Minerals	807,18	838.14	36458.56	807.18	36458,56
b) Agri Business	usiness	812.40	801.91	13174.16	812.40	13174.16
	Total	1619.58	1640,05	49632,71	1619.58	49632.71



l		
į		
1		
	(V)	
ì	m	
l	5	
ı	\rightarrow	
ł	4	

- The above standalone financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 14th February ,...d
- The Company adopted Indian Accounting Standard ("IND AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act. 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Financial results for all periods presented have been prepared in accordance with the recognition and measurement principles of IND AS 34. Limited review of the unaudited financial results for the quarter and nine months ended on 31st December, 2017 has been carried out by the Statutory Auditors. The financial results for the quarter and nine months ended 31st December, 2016 have not been reviewed by the Statutory Auditors and have been presented based on the information compiled by the management after making necessary adjustments to give the true and fair view of the results in accordance with IND AS. Ċ.
- Reconciliation of total comprehensive income to those reported under previous under Generally Accepted Accounting Principles (GAAP) are summarized as below: (m)

Particulars	Quarter Ended Nine month	Nine month
	December 31, ended	ended
	2016	December 31,
		2016
Profit after Tax as reparted under previous GAAP	26.29	-7779.41
Profit after Tax as reported under IND-AS	56,29	-7779,41
Other comprehensive income/(expense)	00.0	00'0
Total comprehensive income as reported under IND-As	26.29	-7779.41

The figures of the previous period have been regrouped/rearranged so as to make them comparable.

In respect of overdue trade receivables, the management has filed recovery suits against the errant parties to recover the amounts. The management is confident of recovery of all such dues and hence no provision is considered necessary. 4 6

For Alchemist Limited By Order of Board

(Whole Time Director) Bikram Bhattacharya

Place: New Delhi

Date: 14/02/18

ANNEXURE MORE THE

ANU AND ASSOCIATES CHARTERED ACCOUNTANTS

1081, SECTOR 27-B, CHANDIGARH - 160 019

PH: 5088800

e-mail: anuandassociates@gmail.com

Independent Auditor's Review Report on Quarterly and Year to Date Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015

To the Board of Directors of Alchemist Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Alchemist Limited ("the Company"), having registered office at Alchemist House, 23-Nehru Place, New Delhi, for the quarter ended 31st December, 2017 and the year to date results for the period 1st April, 2017 to 31st December, 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Attention is invited to Note No. 5 of the accompanying statement, which states that "In respect of overdue trade receivables, the management has filed recovery suits against the erront parties to recover the amounts. The management is confident of recovery of all such dues and hence no provision is considered necessary". However, we are unable to comment on the recoverability of export receivable amounting to Rs. 45645.38 lacs outstanding for more than a year as at the quarter and year to date ended 31st December, 2017, for which no provision is created. The loss to that extent is under stated, the effect however could not be quantified.
- 4. The Company has computed the Depreciation on the tangible fixed assets using straight line method based on the useful life of the assets as prescribed in Schedule II of the Companies Act, 2013 and the management estimates of useful life for tangible and intangible assets not covered by the Schedule II. However, for the assets purchased/commissioned prior to 1st April, 2010, the purchase date of assets has been considered as 1st April, 2010. This treatment not only enhances the useful life of the assets that have already been consumed but has an effect over the depreciation computed. The loss to that extent may be under/over stated and similarly the assets, the effect however could not be quantified.



ANU AND ASSOCIATES CHARTERED ACCOUNTANTS

1081, SECTOR 27-B, CHANDIGARH - 160 019

PH: 5088800

e-mail: anuandassociates@gmail.com

- 5. Based on our review conducted as above, subject to the impact of our observations in paragraph 3 and 4 above, nothing else has come to our attention that causes us to believe that the accompanying statement of un-audited standalone financial results prepared in accordance with applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, SEBI Circulars CIR/CFD/CMD/15/2015 dated 30th November, 2015 and CIR/CFD/FAC/62/2016 dated 5th July, 2016, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. Attention is drawn to the fact that the figures for the corresponding quarter and year to date ended 31st December, 2016, including the reconciliation of net profit under IND AS of the corresponding quarter and year to date with net profit reported under previous GAAP, as included in the accompanying statement of un-audited standalone financial results, have been approved by the Board of Directors but have not been subject to limited review or audit.

Further, attention is drawn to the fact that the comparative financial information of the Company for the quarter and year to date ended 31st December, 2016 prepared in accordance with Indian Accounting Standards (Ind AS) included in this Statement has been reviewed by the predecessor auditor. The report of the predecessor auditor on comparative financial information for the quarter ended 31st December, 2016 dated 10th February, 2017 expressed a qualified opinion.

Our report is not qualified in respect of the matters as specified in paragraph 6 above.

for Anu and Associates Chartered Accountants

Firm Registration No.: 019624N

CA. Parveen Kumar

Partner

Membership No.: 531655

Place: New Delhi

Date: 14th February, 2018